Todd K. Abraham, Ph.D., M.B.A. (At Large Trustee)

Dr. Abraham currently serves as Senior Vice President of Global Research and Nutrition at Mondelez International (formerly Kraft Foods). His 35+ year career spans research and development, marketing, and general management in the food industry. His research and development activities include innovation and product development, nutrition science, analytical responsibilities, technology development, open innovation and knowledge management globally. Dr. Abraham believes that food companies should commit to delivering balanced alternatives to consumers and that addressing public health is part of those companies' corporate responsibility. He advocates the need for partnerships and novel relationships that can address the strategic needs of both partners. In addition to his experience in food technology, Dr. Abraham received his Ph.D. in inorganic chemistry from the University of Pennsylvania and his M.B.A. from the Wharton School, and uses this combination of scientific and business training to understand the unique needs of non-profit organizations.

Gregory E. Amidon, Ph.D. (Pharmaceutical Sciences Trustee)

Dr. Amidon received his Bachelor of Science degree in Medicinal Chemistry (1974) and his Ph.D. in Pharmaceutical Chemistry (1979) from the University of Michigan at Ann Arbor, MI. He joined the University of Michigan, College of Pharmacy as Research Professor of Pharmaceutical Sciences after 28 years in the pharmaceutical industry. Prior to joining the University of Michigan, Dr. Amidon held research positions in pharmaceutical R&D for Pfizer, and its legacy companies Pharmacia, Pharmacia & Upjohn, and The Upjohn Company. He is recognized for his expertise in the physical, chemical and mechanical property characterization of active pharmaceutical ingredients, excipients and products as well as the development of scientific strategies for oral solid dosage form development. His current research interests include oral bioperformance assessment. In addition to his USP activities, Dr. Amidon is a member, Fellow, and 2014-15 President-Elect of American Association of Pharmaceutical Scientists (AAPS). He is the recipient of the 2014 AAPS Research Achievement Award in Physical Pharmacy and Biopharmaceutics and a past recipient of the Ebert Prize from the American Pharmaceutical Association.

Satyanarayana Chava (At Large Trustee)

Dr. Satyanarayana Chava is the Chief Executive Officer at Laurus Labs Limited , which he founded in September 2005. He previously served as Chief Operating Officer of Matrix Laboratories Limited in Hyderabad, where he played a key role in transforming it into a major pharmaceutical company in less than six years. He has more than twenty years of experience in the pharmaceutical industry, specializing in research and development, manufacturing and business development. Dr. Chava has to his credit several breakthroughs in API, process development, and particular expertise in intellectual property - he has authored over 100 patents. He also serves as Chairman of Laurus Infosystems Private Limited, a software development and service provider for life science and mobile technology companies.

Paul Chew, M.D. (Medical Trustee)

Before joining Omada Health, Dr. Paul Chew was Senior Vice-President and Global Chief Medical Officer at Sanofi where he was responsible for the clinical development of innovative therapies for cardiovascular disease and diabetes. In several roles at Sanofi, Dr. Chew worked closely with payers, patient groups, and the full range of healthcare stakeholders.

In addition, he is currently a member of the PhRMA Science & Regulatory Affairs Executive Committee and the Institute of Medicine Value & Science-Driven Healthcare Roundtable. Prior to Sanofi, US Dr. Chew was Vice-President, Global Head of Metabolism and Diabetes at Aventis Pharmaceuticals, 2001-2004. Prior to joining Aventis, Dr. Chew was at the Bristol-Myers Squibb Company, starting in 1992 as Medical Director of Clinical Cardiovascular Development. Dr. Chew held numerous positions of increasing R&D responsibility at BMS; Dr. Chew was Vice President, U.S. Medical Affairs from 1999-2001 where he was responsible for Plavix, Avapro, Glucophage, and Pravachol.

Prior to industry, Dr. Chew was Assistant Professor of Medicine at The Johns Hopkins Hospital, Attending Physician in Radiology, Director of the Pacemaker Clinic and a member of the Interventional Cardiology staff. Research interests included acute interventional cardiology, cardiac biomechanics, and statistical modeling of pericardial biomechanics. Dr. Chew obtained his medical education at The Johns Hopkins School of Medicine, serving his internal medicine training and cardiology fellowship at The Johns Hopkins Hospital. Dr. Chew is board-certified in Internal Medicine and Cardiovascular Diseases.

John E. Courtney, Ph.D. (Treasurer)

Dr. Courtney has served as USP Treasurer since 2010 . He is the Chief Executive Officer for the American Society for Nutrition (ASN), consisting of the world's top researchers and clinical nutritionists, industry and governments in over 100 countries around the world, to advance the knowledge and application of nutrition for the sake of humans and animals. As a seasoned Chief Financial Officer for a 200+ million dollar non-profit organization, he has a thorough understanding of the requirements necessary to successfully perform the responsibilities of Treasurer of USP. He holds a Ph.D. and an MBA with over 20 years of successful Chief Executive Officer and Chief Financial Officer experience.

Timothy R. Franson, B.S. Pharm., M.D. (Past President)

Dr. Franson served as President from 2010-2015. He currently serves as Chief Medical Officer for YourEncore and was previously Senior Vice President of Faegre-BD Consulting. He is former Vice President of Global Regulatory Affairs/Drug Safety for Eli Lilly & Company. Prior to his work at Lilly, Dr. Franson was an Assistant Professor of Medicine (Infectious Diseases) and Hospital Epidemiologist at Medical College of Wisconsin (Milwaukee). Dr. Franson's professional interests include infectious diseases in the elderly (having served as former NIA/NIH RO-1 principal investigator); hospital epidemiology (device associated nosocomial infections); and antibiotic DUR. Dr. Franson served on the Xavier University of Louisiana Board of Trustees from 2002-2008; Regulatory Advisory Board–Centres for Medicines Research International from 2003-2008; Pharmaceutical Research and Manufacturers Association (past chair of Clinical Steering Committee, past chair of GMP Task Force, past chair of FDA Staff Work Group, member-Regulatory Affairs Committee and co-chair of PDUFA-3 coordination/negotiations committee); Auburn University Harrison School of Pharmacy Dean's Advisory Committee; and Drake College of Pharmacy National Advisory Committee. Dr. Franson also served on American Association of Colleges of Pharmacy's Pharmaceutical Education Advisory Committee and the Association of American Medical Colleges-PhRMA Clinical Trials Forum. Dr. Franson was named James Scholar–University of Illinois College of Medicine (1977-78); is a member of Rho Chi Honor Society–Drake University College of Pharmacy; earned Lilly Chairman's Ovation Award (2002); and was awarded Sagamore of the Wabash by Indiana Governor Mitchell E. Daniels Jr. for community service. He now serves on the Board of Directors for the Critical Path Institute and is Adjunct Professor of Clinical Pharmacology at Indiana University School of Medicine.

Jesse L. Goodman, M.D., M.P.H. (President)

Dr. Goodman is Professor of Medicine at Georgetown University, and directs a new Center on Medical Product Access, Safety and Stewardship (COMPASS) focused on informing science based policy to address public health needs. He is Board Certified in Internal Medicine, Infectious Diseases and Oncology and serves as an infectious diseases consultant at Georgetown University, DC Veterans' Affairs and Walter Reed Medical Centers. Until 2014 he was FDA's Chief Scientist, leading crosscutting scientific efforts, including public health preparedness and medical countermeasures. Before that, he directed FDA's Center for Biologics Evaluation and Research (CBER), supporting innovative regulatory approaches to vaccines and other biologics and spearheading unique public-private efforts to address public health challenges such as West Nile Virus, human tissue safety, and influenza vaccine development and availability. As Senior Advisor to the Commissioner, he initiated the first US Task Force on Antimicrobial Resistance (AMR). He helped in developing the Global Vaccine Action Plan and currently serves on WHO's Ebola Vaccine Advisory Group. Previously, he was Chief of Infectious Diseases at the University of Minnesota. A Harvard graduate, he received his M.D. from Albert Einstein and post-doctoral training at the University of Pennsylvania and UCLA, where he was Chief Resident. He has been elected to the Institute of Medicine of the National Academy of Sciences.

Laura Herman, M.B.A., M.A. (Public Trustee)

Laura Herman has worked to address the question "Why are the poor people poor?" over and over again, throughout the more than 50 countries she has visited in the last 25 years. While the specific answers may vary, they consistently include a reference to poor healthcare. Dr. Herman's international interest became evident while she was in university as the Berlin Wall came down, and expanded to the developing world. As a management consultant at Deloitte in the mid-1990s she learned the consulting trade, and whenever she had the chance to travel or volunteer, she found herself back in the developing world, and wondering why all the philanthropic projects yielded such paltry results. She pursued her MBA and MA in International Policy from Stanford with the explicit intent of developing a consulting firm that would improve the effectiveness of philanthropy in the global south, starting with a focus on healthcare. Laura joined the founding team of FSG (a 150-person firm with offices in the US, Europe and India) 15 years ago and has been committed to advising corporations, foundations, governments and NGOs on their strategies for creating social impact in the developing world ever since. She is a Managing Director, part of the firm's executive leadership team, oversees client engagements, speaks at global conferences and authors articles to share the new approaches that emerge from FSG's work. She has explored a range of health issues, but at the heart of nearly every issue has been the problem of counterfeit or ineffective medicines. Regardless of the improvements that could be made in training, infrastructure, health seeking behavior, or policy, if the medicines were useless, the patient suffered needlessly.

Robert J. Meyer, M.D. (Medical Sciences Trustee)

Dr. Meyer is an academically trained pulmonologist and critical care specialist and a regulatory science expert by vocation. He is currently the Director of the Virginia Center for Translational and Regulatory Sciences at the University of Virginia's School of Medicine, as well as being an Associate Professor of Public Health Sciences Prior to joining the faculty at UVA, Dr. Meyer was Vice President and head, Global Regulatory Strategy, Policy and Safety at Merck Research Laboratories (MRL) where he was responsible for all regulatory strategy and operations, global regulatory policy and intelligence, and global product safety and pharmacovigilance. At MRL, Dr. Meyer served on Development Review Committee for all clinical stages, the Safety Review Committee and chaired the Development Policy Committee. Dr. Meyer chaired the Regulatory Affairs Coordinating Committee for Pharmaceutical Research and Manufacturers of America (PhRMA) from 2012-13 and served as a key PhRMA negotiator on PDUFA V.

Prior to Merck, Dr. Meyer was at the FDA for 13 years. His last position at the FDA was as the Director for the Office of Drug Evaluation II (ODEII) within CDER, with responsibilities for pulmonary and allergy, metabolic and endocrine, and analgesics, anesthetics and rheumatologic drug products from 2002 - 2007. Besides his formal role, Dr. Meyer was involved in several CDER initiatives, amongst them chairing the development of the Pre-Market Risk Assessment guidance. Additionally, he participated with the FDA negotiation team in the PDUFA III and IV. While at FDA and currently, Dr. Meyer served as an expert to the Medical Aerosols Technical Options Committee of the United Nations.

Marilyn K. Speedie, Ph.D. (Pharmaceutical Sciences Trustee)

Dr. Marilyn Speedie was educated as a pharmacist and then as a Ph.D. scientist at Purdue University School of Pharmacy and Pharmaceutical Sciences with a focus of her Ph.D. work on antibiotic biosynthesis and enzymology. She began her academic career and proceeded through the academic ranks at the University of Maryland School of Pharmacy. Her research was focused on microbial transformations and enzymology and ultimately became biotechnology focused as that science emerged. She completed her career there as Chair of the Department of Pharmaceutical Sciences, a position that allowed her to gain a broader general knowledge of the pharmaceutical sciences as a whole. In 1996 Dr. Speedie moved to the University of Minnesota College of Pharmacy as Dean, where she has been involved in leading all missions of the college, including advancing professional and interprofessional practice, as well as science. She has served on the USP Board of Directors for the past 5 years. In 2014 she was awarded APhA's Remington Medal for her contributions to the profession of pharmacy.

Thomas R. Temple, B.S.Pharm., M.S., FAPhA (At Large Trustee)

Tom Temple is the Director of Strategic Communication for the University of Iowa College of Pharmacy and President of Thomas Temple Consulting. He had previously served for 33 years as the Chief Executive Officer and Executive VP for the Iowa Pharmacy Association (IPA). Mr. Temple received a BS Degree in Biology from Northern Illinois University (1971), a professional degree in Pharmacy from the University of Illinois (1977), and an MS Degree in Pharmacy Administration from the University of Iowa (1977).

Mr. Temple is a member of several professional organizations including the IPA, the American Pharmacists Association (APhA), and the National Alliance of State Pharmacy Association (NASPA). He serves as a member of several governing boards for organizations including the USP, the APhA Foundation, the Alliance for Patient Medication Safety (APMS), and the University of Iowa Alumni Association. Additionally, Mr. Temple has served on Advisory Boards for the Medical Alert Foundation, the Accreditation Council on Pharmaceutical Education (ACPE), Pharmacy Technician Certification Board, Drake College of Pharmacy, University of Illinois College of Pharmacy, and the University of Iowa College of Pharmacy. He has also served an advisory consultant to Upjohn, Glaxo SmithKline, Merck, Hoechst Marion Rousell, and PCS.

Mr. Temple's leadership has been recognized through the receipt of several awards including APhA's Hugo H. Schaefer Award, Gloria Neimeyer-Franke Leadership Mentor Award, IPA's Robert G. Gibbs Award, the University of Illinois College of Pharmacy Alumnus of the Year Award, the University of Iowa College of Pharmacy Alumnus of the Year Award, the University of Iowa Distinguished Alumni Award, the Drake University Weaver Medal of Honor, and the University of Iowa Osterhaus Medal for Lifetime Achievement.

Gail R. Wilensky, Ph.D. (At Large Trustee)

Dr. Wilensky, an economist and senior fellow at Project HOPE, an international health foundation, directed Medicare and Medicaid programs, served the White House as a senior adviser on health and welfare issues to President GHW Bush. She was the first chair of the Medicare Payment Advisory Commission.

Dr. Wilensky currently serves as a trustee of the Combined Benefits Fund of the United Mine Workers of America and the National Opinion Research Center, is on the Board of Regents of the Uniformed Services University of the Health Sciences (USUHS), the Visiting Committee of the Harvard Medical School and the Board of Directors of the Geisinger Health System Foundation. An elected member of Institute of Medicine, served two terms on its governing council, chairs the Healthcare Service Board and is currently a director of United Health Group, Quest Diagnostics and BrainScope. She testifies before Congressional committees and speaks nationally and internationally. Received a bachelor’s degree in psychology and a Ph.D. in economics at the University of Michigan and has received several honorary degrees.

Susan C. Winckler, R.Ph., J.D. (At Large Trustee)

In managing the DC office of Leavitt Partners, a national health-care consulting firm, Ms. Winckler advises corporate executives on policy and business matters, such as Medicare/Medicaid, FDA practices and alternative payment models. As CEO of the Food & Drug Law Institute, she provided attorneys, regulators, industry leaders and consumers with journals, meetings and a neutral forum for addressing domestic and global issues.

As FDA Chief of Staff, Ms. Winckler managed the Commissioner's office; served as his/her senior staff adviser; analyzed policies; and represented FDA before myriad government and external stakeholders. She simultaneously led FDA's Offices of Legislation, External Relations, Public Affairs and Executive Secretariat.

As APhA Vice President Policy/Communications and Staff Counsel, Ms. Winckler served as the association's lead spokesperson and senior liaison to Congress, the executive branch, state associations and allied groups. Over the prior 9 years, she held several policy and practice-related jobs. Ms. Winckler earned a B.S. from the University of Iowa College of Pharmacy and her J.D. *magna cum laude* from Georgetown University Law Center. She is an APhA Fellow.